Steady State Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Steady State 400 mg of Viramune® (200 mg BID), in HIV-1 Infected Subjects, an Open Label, Non Randomised, Multidose and Multistage Parallel Group Study. (ERVIR)
收藏DataCite Commons2024-12-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00003727/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The objective was to establish the pharmacokinetic (PK) profile at steady state of two different nevirapine (NVP) extended release (XR) formulations at 300 mg or 400 mg daily (QD) under fasted and fed conditions in comparison with the commercially available NVP immediate release (IR) tablet at 200 mg BID (400 mg/day).
提供机构：
Vivli
创建时间：
2019-04-12
